|
1
|
Gion M, Mione R, Leon AE and Dittadi R:
Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in
primary breast cancer. Clin Chem. 45:630–637. 1999.
|
|
2
|
Gion M, Mione R, Leon AE, Luftner D,
Molina R, Possinger K and Robertson JF: CA27.29: a valuable marker
for breast cancer management. A confirmatory multicentric study on
603 cases. Eur J Cancer. 37:355–363. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luftner D, Luke C and Possinger K: Serum
HER-2/neu in the management of breast cancer patients. Clin
Biochem. 36:233–240. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y, Fang F, Shi C, et al: Evaluation
of a method for the simultaneous detection of multiple tumor
markers using a multiplex suspension bead array. Clin Biochem.
45:1394–1398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nicolini A, Carpi A, Ferrari P and Rossi
G: Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the
metastatic progression in endocrine-dependent breast cancer
patients: a retrospective longitudinal study. Cancer Lett.
263:122–129. 2008. View Article : Google Scholar
|
|
6
|
Flower DR: The lipocalin protein family:
structure and function. Biochem J. 318(Pt 1): 1–14. 1996.
|
|
7
|
Triebel S, Blaser J, Reinke H and
Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a
component of the 125 kDa form of human gelatinase. FEBS Lett.
314:386–388. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haase M, Bellomo R, Devarajan P,
Schlattmann P and Haase-Fielitz A: Accuracy of neutrophil
gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis
in acute kidney injury: a systematic review and meta-analysis. Am J
Kidney Dis. 54:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kjeldsen L, Johnsen AH, Sengelov H and
Borregaard N: Isolation and primary structure of NGAL, a novel
protein associated with human neutrophil gelatinase. J Biol Chem.
268:10425–10432. 1993.PubMed/NCBI
|
|
10
|
Hu L, Hittelman W, Lu T, et al: NGAL
decreases E-cadherin- mediated cell-cell adhesion and increases
cell motility and invasion through Rac1 in colon carcinoma cells.
Lab Invest. 89:531–548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang XF, Zhang Y, Zhang XH, et al:
Clinical significance of Neutrophil gelatinase-associated lipocalin
(NGAL) expression in primary rectal cancer. BMC Cancer. 9:1342009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kubben FJ, Sier CF, Hawinkels LJ, et al:
Clinical evidence for a protective role of lipocalin-2 against
MMP-9 autodegradation and the impact for gastric cancer. Eur J
Cancer. 43:1869–1876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Xu L, Xiao D, et al: Upregulation
of neutrophil gelatinase-associated lipocalin in oesophageal
squamous cell carcinoma: significant correlation with cell
differentiation and tumour invasion. J Clin Pathol. 60:555–561.
2007. View Article : Google Scholar
|
|
14
|
Friedl A, Stoesz SP, Buckley P and Gould
MN: Neutrophil gelatinase-associated lipocalin in normal and
neoplastic human tissues. Cell type-specific pattern of expression.
Histochem J. 31:433–441. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li LG, Zhou T and Hou YM: Expression and
functional analysis of NGAL gene in human hepatocellular carcinoma.
J Fudan Univ (Nat Sci). 51:91–98. 2012.
|
|
16
|
Iannetti A, Pacifico F, Acquaviva R, et
al: The neutrophil gelatinase-associated lipocalin (NGAL), a
NF-kappaB-regulated gene, is a survival factor for thyroid
neoplastic cells. Proc Natl Acad Sci USA. 105:14058–14063. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Furutani M, Arii S, Mizumoto M, Kato M and
Imamura M: Identification of a neutrophil gelatinase-associated
lipocalin mRNA in human pancreatic cancers using a modified signal
sequence trap method. Cancer Lett. 122:209–214. 1998. View Article : Google Scholar
|
|
18
|
Laurell H, Bouisson M, Berthelemy P, et
al: Identification of biomarkers of human pancreatic
adenocarcinomas by expression profiling and validation with gene
expression analysis in endoscopic ultrasound-guided fine needle
aspiration samples. World J Gastroenterol. 12:3344–3351. 2006.
|
|
19
|
Tong Z, Kunnumakkara AB, Wang H, et al:
Neutrophil gelatinase-associated lipocalin: a novel suppressor of
invasion and angiogenesis in pancreatic cancer. Cancer Res.
68:6100–6108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mahadevan NR, Rodvold J, Almanza G, Perez
AF, Wheeler MC and Zanetti M: ER stress drives Lipocalin 2
upregulation in prostate cancer cells in an NF-κB-dependent manner.
BMC Cancer. 11:2292011.PubMed/NCBI
|
|
21
|
Villalva C, Sorel N, Bonnet ML, et al:
Neutrophil gelatinase-associated lipocalin expression in chronic
myeloid leukemia. Leuk Lymphoma. 49:984–988. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leng X, Lin H, Ding T, et al: Lipocalin 2
is required for BCR-ABL-induced tumorigenesis. Oncogene.
27:6110–6119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jones C, Mackay A, Grigoriadis A, et al:
Expression profiling of purified normal human luminal and
myoepithelial breast cells: identification of novel prognostic
markers for breast cancer. Cancer Res. 64:3037–3045. 2004.
View Article : Google Scholar
|
|
24
|
Yang J, Bielenberg DR, Rodig SJ, et al:
Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci
USA. 106:3913–3918. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bauer M, Eickhoff JC, Gould MN, Mundhenke
C, Maass N and Friedl A: Neutrophil gelatinase-associated lipocalin
(NGAL) is a predictor of poor prognosis in human primary breast
cancer. Breast Cancer Res Treat. 108:389–397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wenners AS, Mehta K, Loibl S, et al:
Neutrophil gelatinase-associated lipocalin (NGAL) predicts response
to neoadjuvant chemotherapy and clinical outcome in primary human
breast cancer. PLoS One. 7:e458262012. View Article : Google Scholar
|
|
27
|
Stoesz SP, Friedl A, Haag JD, Lindstrom
MJ, Clark GM and Gould MN: Heterogeneous expression of the
lipocalin NGAL in primary breast cancers. Int J Cancer. 79:565–572.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Provatopoulou X, Gounaris A, Kalogera E,
et al: Circulating levels of matrix metalloproteinase-9 (MMP-9),
neutrophil gelatinase-associated lipocalin (NGAL) and their complex
MMP-9/NGAL in breast cancer disease. BMC Cancer. 9:3902009.
View Article : Google Scholar
|
|
29
|
Zhang XF, Zhou SM, Wan L, et al:
Relationship between NGAL expression and progression, metastasis
and prognosis of breast cancer. J Pract Oncol. 23:206–210.
2008.
|
|
30
|
Lv CG and Qi FJ: Expression of NGAL and
MMP-9 protein in invasive breast cancer and its clinical
application. Guangdong Med J. 32:1287–1289. 2011.
|
|
31
|
Wang XH, Guo YY and Gou XM: Expression of
NGAL in breast cancer and its clinical application. China Pract
Med. 6:43–45. 2011.
|
|
32
|
Qiu JM: Clinical significance of
determination in tumor cells NGAL levels of breast cancer patients
with immuno-histochemistry. J Radioimmunol. 25:546–548. 2012.
|
|
33
|
Stuckey R, Aldridge T, Lim FL, et al:
Induction of iron homeostasis genes during estrogen-induced uterine
growth and differentiation. Mol Cell Endocrinol. 253:22–29. 2006.
View Article : Google Scholar
|
